Darusentan

DSarusentan

Darusentan (LU-135252; HMR-4005) is a pharmaceutical compound classified as an endothelin receptor antagonist. Its primary therapeutic aim is towards the potential treatment of uncontrolled hypertension. The development and licensing timeline of Darusentan reveals collaborations between several prominent pharmaceutical entities.

Development and Licensing

• Origin: Darusentan was initially identified and explored by Abbott Laboratories for its endothelin receptor antagonistic properties.
• Gilead Colorado Collaboration:
  • Darusentan's further development for uncontrolled hypertension has been spearheaded by Gilead Colorado, a subsidiary of the larger Gilead Sciences firm.
  • This development is conducted under a license obtained from Abbott Laboratories.
• Licensing to Myogen:
  • In June 2003, Myogen acquired the rights to Darusentan from Abbott, but with a specific focus on its potential application within the oncology sector.

Clinical Trials

Phase III Trial

• Initiation Date: May 2007
• Design:
  • The trial was designed as a randomized, double-blind, active control, parallel assignment. The primary goals were to assess both safety and efficacy.
  • The study was initiated for subjects who had already completed the maintenance period of the DAR-312 study.
• Objective: The Phase III trial was integral in understanding Darusentan's role and effectiveness in treating uncontrolled hypertension, with a particular focus on any possible side-effects and contraindications.

Mechanism of Action

• Endothelin Receptor Antagonism: By inhibiting the activity of endothelin receptors, Darusentan can potentially counteract the vasoconstrictive effects of endothelin peptides, thus assisting in the reduction of blood pressure.

Potential Applications

• Hypertension: Darusentan is primarily being explored for its efficacy in treating uncontrolled hypertension.
• Oncology: Myogen's interest in Darusentan hints at potential applications within the realm of cancer treatment, although specific targets and mechanisms in this context need further exploration.

Conclusion

Darusentan represents a significant leap in the research and development of endothelin receptor antagonists. As clinical trials progress and more data becomes available, the full therapeutic potential of Darusentan will become clearer, potentially offering new treatments for hypertension and possibly even cancer-related conditions.

See Also

• Endothelin Receptor Antagonists
• Hypertension
• Gilead Sciences
• Abbott Laboratories
• Ambrisentan